CGP-7930 was the first positive allosteric modulator of GABAB receptors described in literature.[1][2][3][4] CGP7930 is also a GABAA receptor positive allosteric modulator and a blocker of Potassium channels.[5]
Identifiers | |
---|---|
| |
CAS Number |
|
PubChem CID |
|
IUPHAR/BPS |
|
ChemSpider |
|
UNII |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C19H32O2 |
Molar mass | 292.463 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |
CGP7930 was developed in Novartis and has been used extensively for scientific research. It has anxiolytic effects in animal studies,[6][7] and has a synergistic effect with GABAB agonists such as baclofen and GHB,[8][9] as well as reducing self-administration of alcoholic drinks and cocaine.[10][11]